P11 Tyrosine Kinase Inhibitor Use in Pulmonary Adenocarcinoma

Thorax - United Kingdom
doi 10.1136/thoraxjnl-2013-204457.161
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Tyrosine Kinase Inhibitor–Induced Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2018English

Complications Associated With Perioperative Use of Tyrosine Kinase Inhibitor in Cytoreductive Nephrectomy

Scientific Reports
Multidisciplinary
2019English

Tyrosine Kinase Inhibitor and Target Therapy

2013English

P030 Prognostic Factors for Advanced Lung Adenocarcinoma Patients Who Received Tyrosine Kinase Inhibitor and Radiotherapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Different Mutational Characteristics of the Subsets of EGFR-tyrosine Kinase Inhibitor Sensitizing Mutation-Positive Lung Adenocarcinoma

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Evaluation of a Tyrosine Kinase Peptide Microarray for Tyrosine Kinase Inhibitor Therapy Selection in Cancer

Experimental & Molecular Medicine
2016English

Ibrutinib: The First Bruton's Tyrosine Kinase Inhibitor

Prescriber
Pharmacology
2018English

Targeting Tumour Microenvironment by Tyrosine Kinase Inhibitor

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2018English

Novel Use of N-Acetylcysteine in Management of Tyrosine Kinase Inhibitor Induced Acute Liver Injury

Cureus
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy